Research News

9 October 2024

India evolving as antimicrobial stewardship

Study finds that in contrast to developed countries that kept resistance levels under control, a considerable increase in resistance to various classes of antibiotics occurred in ESKAPE pathogens in India over the 2010-2020 decade. The study is published in the International Journal of Antimicrobial Agents.

8 October 2024

WHO adds an HPV vaccine for single-dose use

WHO announced that a fourth WHO-prequalified human papillomavirus vaccine product, Cecolin has been confirmed for use in a single-dose schedule. The decision is made based on new data on the product that fulfilled the criteria set out in the WHO 2022 recommendations for alternative, off-label use of HPV vaccines in single-dose schedules.

30 September 2024

Scientists discover gene responsible for rare, inherited eye disease

Scientists at the National Eye Institute and their colleagues have identified a gene responsible for some inherited retinal diseases, which are a group of disorders that damage the eyes light-sensing retina and threatens vision. Though IRDs affect more than 2 million people worldwide, each individual disease is rare, complicating efforts to identify enough people to study and conduct clinical trials to develop treatment.

30 September 2024

Scientists design new drug to fight malaria

A team led by scientists at UC Riverside, UC Irvine, and Yale School of Medicine has now designed a new drug against malaria and identified its mechanism of action. The researchers found the drug, called MED6-189, is effective against drug-sensitive and drug-resistant P. falciparum strains in vitro as well as in a humanized mouse model the mice were engineered to have human blood.

23 September 2024

FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration

The U.S. Food and Drug Administration approved FluMist for self- or caregiver-administration. FluMist is approved for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. FluMist is sprayed into the nose and has been used safely and effectively for many years. It was initially approved by the FDA in 2003 for use in individuals 5 through 49 years of age, and in 2007, the FDA approved the use of FluMist to include children 2 through 5 years of age.

23 September 2024

Sarclisa approved in the US as the first anti-CD38 therapy

The US Food and Drug Administration has approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone as a first line treatment option for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant

20 September 2024

Antiviral-Resistant Variants of SARS-CoV-2 Can Emerge in Immunocompromised People

Researchers isolated SARS-CoV-2 strains, which are drug resistant with mutations to the nsp12 protein that is the target of remdesivir and another variant with mutations to the nsp5 protein, the target of Paxlovid. These mutations help the virus persist in people with compromised immunity despite common antiviral treatments.

20 September 2024

NUS scientists discover novel approach to rejuvenate aged egg cells

Researchers from the Mechanobiology Institute at NUS and the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality , based at the NUS Yong Loo Lin School of Medicine, have developed an innovative technique to significantly enhance the reproductive potential of aged oocytes, or immature egg cells, potentially paving the way for better outcomes of assisted reproductive technologies, such as in-vitro fertilisation , for older females.

12 September 2024

Alopexx Announces Collaboration with Bharat Biotech for the Development and Commercialization of Broad-Spectrum Anti-Microbial Vaccine AV0328

Alopexx, Inc., a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and parasitic infections, announced a collaboration with Bharat Biotech for the co-development and commercialization of Alopexxs proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low income and lower middle-income countries.

12 September 2024

Newly Discovered Antimicrobial Could Prevent or Treat Cholera

More than a million people each year die from infections by pathogens that are resistant to antimicrobials, and the problem is growing. Meanwhile, the discovery of new antimicrobials that can help stem the tide has not kept pace.

Search

India evolving as antimicrobial stewardship

RECOMMENDED POSTS

Subscribe with us

Jobs by Category